Photocure ASA Reports Strong First Quarter Performance for 2026

Photocure ASA, known as a key player in bladder cancer solutions, has announced impressive financial results for the first quarter of 2026. The company reported revenues from its flagship products, Hexvix® and Cysview®, amounting to NOK 139.0 million, a notable increase from NOK 125.3 million in the same quarter last year. Adjusted EBITDA for the company also saw a promising rise to NOK 15.3 million from NOK 9.7 million in Q1 2025.

Growth Trajectory

The positive trajectory for Photocure reflects sustained growth across multiple markets, particularly in North America and Europe. Dan Schneider, the company's President and CEO, stated that the results indicate accelerating adoption rates for blue-light cystoscopy technology, reinforcing Photocure's solid execution of both its commercial and strategic priorities. As part of this growth strategy, the company has successfully installed 11 new Saphira towers across the U.S., a move that will undoubtedly enhance procedural penetration further.

As of the end of Q1 2026, Photocure had 413 active accounts in the U.S., demonstrating a remarkable 21% increase compared to the previous year. This expansion is complemented by the installation of 75 Olympus Visera Elite III BLC-capable systems across Europe since its launch last year.

Comprehensive Financial Overview

Photocure's total revenues reached NOK 264.6 million for the quarter, marking a substantial increase from NOK 125.3 million in Q1 2025. The revenue jump was significantly bolstered by milestone payments of NOK 125.6 million from the approval for Cevira in China and acceptance of the marketing authorization application in Europe.

The reported EBITDA stood at NOK 128.3 million, compared to a mere NOK 1.8 million in Q1 2025, while EBIT climbed to NOK 120.7 million from negative figures the prior year. Cash reserves also remained robust at NOK 192.7 million at the quarter's close, indicating sound financial health.

Regulatory and Market Developments

An important regulatory development that could favorably impact Photocure’s business environment is the FDA’s outlined pathway for the reclassification of diagnostic endoscopic light source systems. This potential change, expected to unfold in the latter half of 2026, aims to create a more predictable regulatory framework for blue-light cystoscopy equipment in the U.S. market. Schneider emphasized that this reclassification could unlock a significantly larger commercial opportunity for Photocure.

Additionally, partners of Photocure, Richard Wolf and Asieris, received notable approval for the System blue BLC platform in China, which will complement Hexvix following prior approvals, thereby creating a fully integrated product offering.

In Europe, the recent CE mark for compatible blue-light systems from Stryker underscores the growing recognition of blue-light cystoscopy, setting the stage for broader adoption in bladder cancer management.

Cevira: A Milestone in Cancer Treatment

Cevira, which Photocure originally developed, has been recognized as a first-in-class non-invasive therapy for cervical precancerous lesions after its approval by China’s National Medical Products Administration (NMPA). The expert consensus in China endorsing Cevira with Level 1A evidence further strengthens its clinical adoption potential. In Europe, the European Medicines Agency has accepted the Marketing Authorization Application for Cevira, further indicating its promising impact on patient care.

Moving forward, Photocure is committed to expanding its integrated diagnostic platform and leveraging its commercial strengths in vital regions. They have recently made a strategic investment in precision diagnostics through a partnership with Vesica Health, a company working on developing tests for early bladder cancer detection.

Looking Ahead

Photocure remains optimistic about continued growth, forecasting product revenue growth between 7%-11% for 2026 on a constant currency basis. The company’s focus on operational efficiency and strategic enhancements positions it well for long-term shareholder value. Schneider concluded, “We remain confident in Photocure's momentum and continued positive trajectory across all regions.”

This foundational growth, paired with strategic regulatory navigation and partnerships, entitles Photocure to anticipate successful advancements in the bladder cancer diagnostic field.

For more insights, the full financial report for Q1 2026 is available on Photocure's official website. The company will host a live webcast for analysts on May 7, 2026, to discuss these results further.